CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use

Most people pick CJC 1295 with DAC because fewer injections sounds like the smarter choice, and on the surface that logic holds up. But DAC does not just change how often you inject. It changes what your pituitary actually experiences, and that difference determines whether the compound works the way you intended it to.

To understand why that matters, you need the full picture first.

Your pituitary gland releases growth hormone in pulses, not as a steady stream, and those pulses are driven by a signaling molecule called GHRH, which stands for growth hormone releasing hormone. CJC 1295 is a synthetic analog of GHRH, meaning it mimics that signal at the pituitary and tells it to release a burst of growth hormone. That burst flows into the bloodstream, reaches your tissues, and drives the effects you are after, things like fat breakdown and tissue repair. Between those pulses, growth hormone levels drop back down to a low baseline, and that valley matters just as much as the peak.

CJC 1295 without DAC fits into that system cleanly. It has a half life of roughly 30 minutes, which means it triggers a growth hormone pulse and then clears out relatively quickly, and your body's own pulses continue firing between doses on their own schedule. The pattern stays pulsatile.

DAC changes the entire operating condition.

DAC stands for drug affinity complex, and what it does is allow CJC 1295 to bind to albumin, a protein that circulates in your blood, and that binding extends the half life from roughly 30 minutes to somewhere between 5.8 and 8.1 days depending on the individual. That number comes directly from the Teichman study published in 2006, which measured CJC 1295 DAC pharmacokinetics in healthy adults. The compound is essentially hitching a ride on a long-lived protein and slowly releasing from it over the course of a week.

The pituitary still fires its own pulses during that time. The Ionescu study from 2006 confirmed that pulse frequency and magnitude are preserved with CJC 1295 DAC, so pulses are still happening. But here is the problem. The baseline level of growth hormone between those pulses, what researchers call the trough, was elevated 7.5 times above normal. The valleys are filled in. Instead of a pulsatile pattern that rises and falls clearly, you have a relatively flat, chronically elevated growth hormone environment with pulses riding on top of a high floor.

That distinction between pulsatile and continuous delivery is not a minor pharmacological detail. It is the whole mechanism that determines whether you get the metabolic effect you are looking for.

The Surya study from 2009 tested exactly this question in humans. Researchers delivered growth hormone in a pulsatile pattern to one group and a continuous pattern to another, and then measured lipolysis, which is the process of breaking down stored fat for fuel. The pulsatile group saw lipolysis nearly double from a baseline of 4.1 up to 7.1 micromoles per kilogram per minute. The continuous group went from 4.1 to 4.8, which was not statistically different from doing nothing. The same total amount of growth hormone exposure, delivered differently, produced completely opposite outcomes for fat metabolism.

The reason for this likely comes down to how receptors respond to sustained stimulation. When a receptor gets a pulse of a signal and then gets a break, it resets and is ready to respond again. When it is stimulated continuously without a break, it starts to downregulate, meaning it reduces its own sensitivity to that signal. There is research showing that continuous GHRH exposure for as little as four hours can reduce GHRH receptor expression in the pituitary to 49 to 54 percent of baseline, and that effect is dose-dependent, so more continuous exposure means more receptor blunting. DAC does not expose the pituitary to four hours of stimulation. It exposes it to roughly a week. The long-term implications of that on receptor sensitivity are not fully characterized in humans, but the directional signal from the receptor biology is not favorable.

This is where the choice between DAC and no DAC stops being about injection frequency and starts being about what you actually want the compound to do.

The entire reason to choose a secretagogue like CJC 1295 over injecting growth hormone directly is that a secretagogue works through your own pituitary, preserving the pulsatile pattern and keeping your natural regulatory system intact. That is the advantage. DAC partially dismantles that advantage by keeping your trough elevated to a point where the pattern looks more like continuous exposure than true pulsatile delivery.

And if continuous growth hormone elevation is the goal, growth hormone itself does that with a known, controllable dose and decades of clinical data behind it. DAC leaves you in a position where you have given up the pulsatile benefit of a secretagogue but you have not gained the precision or the data backing of direct growth hormone use.

CJC 1295 without DAC, used at a frequency that works with your natural pulse pattern rather than overriding it, is the version that actually uses the compound for what secretagogues are designed to do.

The upgrade is not fewer injections. The upgrade is keeping the pattern that makes the compound work in the first place.

---

References

1. Surya S et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;948:2828-2834 — Pulsatile GH nearly doubled lipolysis 7.1 vs 4.1 baseline, continuous was not significantly different from baseline 4.8 vs 4.1. Source
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;9112:4792-4797 — CJC-1295 DAC preserved pulse frequency and magnitude but elevated basal trough GH 7.5-fold. Source
3. Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;913:799-805 — CJC-1295 DAC half-life 5.8-8.1 days due to albumin binding. Source
4. Aleppo G et al. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;1383:1058-1065 — Continuous GHRH exposure for 4 hours reduced GHRH receptor mRNA to 49-54% of baseline, dose-dependent and cAMP-mediated. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness